Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.
Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.
Medicare to cut payments for cancer drugs by 2-8%. ASCO estimates total cut in reimbursement at $500 million.
Richard Bloch, advocate for patient information services, dead at 78.
STAR completes enrollment.
NCI forms pediatric central IRB.
Funding opportunities listed.
July issue of Business & Regulatory report (8 additional pages) included.
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- George Sigounas named the first-ever chief science advisor at NCI
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- Makary: Level of evidence is an artificial and dogmatic construct